Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2

NEXT STORY
Report from the Annual General Meeting of Immunicum AB (publ) on April 25, 2018
PREV STORY
Sharps Compliance Reports Fiscal 2018 Third Quarter Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Adaptimmune to Provide Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress

PHILADELPHIA and OXFORD, United Kingdom, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ...

author_avatar
NASDAQ Market News

Helix BioPharma Corp.: First Patient Dosed in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin

author_avatar
NASDAQ Market News

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children ...

author_avatar
NASDAQ Market News